Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model |
| |
Authors: | Koji Ishii Hideki Hasegawa Noriyo Nagata Yasushi Ami Shuetsu Fukushi Fumihiro Taguchi Yasuko Tsunetsugu-Yokota |
| |
Affiliation: | Department of Virology I;, Department of Virology II;, Department of Virology III;, Department of Pathology;, Division of Experimental Animals Research;and Department of Immunology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan |
| |
Abstract: | We evaluated the efficacy of three SARS vaccine candidates in a murine SARS model utilizing low-virulence Pp and SARS-CoV coinfection. Vaccinated mice were protected from severe respiratory disease in parallel with a low virus titer in the lungs and a high neutralizing antibody titer in the plasma. Importantly, the administration of spike protein-specific neutralizing monoclonal antibody protected mice from the disease, indicating that the neutralization is sufficient for protection. Moreover, a high level of IL-6 and MCP-1 production, but not other 18 cytokines tested, on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection. |
| |
Keywords: | coronavirus Pasteurella pneumotropica severe acute respiratory syndrome (SARS) |
|
|